Cite
van der Aar E, Deckx H, Dupont S, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip. Clin Pharmacol Drug Dev. 2021;11(1):112-122doi: 10.1002/cpdd.1042.
van der Aar, E., Deckx, H., Dupont, S., Fieuw, A., Delage, S., Larsson, S., Struglics, A., Lohmander, L. S., Lalande, A., Leroux, E., Amantini, D., & Passier, P. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip. Clinical pharmacology in drug development, 11(1), 112-122. https://doi.org/10.1002/cpdd.1042
van der Aar, Ellen, et al. "Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip." Clinical pharmacology in drug development vol. 11,1 (2022): 112-122. doi: https://doi.org/10.1002/cpdd.1042
van der Aar E, Deckx H, Dupont S, Fieuw A, Delage S, Larsson S, Struglics A, Lohmander LS, Lalande A, Leroux E, Amantini D, Passier P. Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip. Clin Pharmacol Drug Dev. 2022 Jan;11(1):112-122. doi: 10.1002/cpdd.1042. Epub 2021 Dec 02. PMID: 34859612.
Copy
Download .nbib